CClinicalTrials.gg
Not yet recruitingNCT07541651Updated Apr 21, 2026

Study on Eye-Brain Cross-Organ Mapping and Systemic Disease Association Based on Multimodal Big Data

An observational study in Cataract, Vitreous Hemorrhage and Diabetic Eye Diseases, sponsored by Beijing Friendship Hospital. Not yet recruiting. Per ClinicalTrials.gov, last updated 2026-04-21.

Sponsored by Beijing Friendship Hospital · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
208,000
Sex
All
01

Study summary

This project integrates multimodal eye data (CFP, OCT, OCTA) from 50,000 cases, brain MR data from 150,000 cases, and ICD diagnoses, medical orders, and test results from an eye-brain paired cohort of 8,000 cases to construct an eye-brain cross-modal mapping model and an eye-brain-systemic disease association model. It aims to clarify the quantitative associations between multimodal ocular features and brain structural and vascular characteristics as well as systemic disease ICD diagnoses, thereby uncovering the cross-organ and cross-modal linkage mechanisms between the eye and brain. Ultimately, it seeks to achieve mapping and prediction of brain imaging features based on ocular data, enable ocular-based diagnosis and prediction of various diseases, and contribute significantly to early disease screening, risk stratification, and optimization of clinical diagnosis and treatment.

02

Conditions studied

  • Cataract
  • Vitreous Hemorrhage
  • Diabetic Eye Diseases
  • Cerebral Small Vessel Disease
  • Cerebrovascular Stenosis
03

In context

Cataract

1,701 studies on the registry are indexed under Cataract; 230 are open to participants now.

This study's planned enrollment of 208,000 is above the median of 81 across 484 observational studies indexed under Cataract.

Browse Cataract studies →

Lead sponsor

Beijing Friendship Hospital is the lead sponsor of 216 studies on the registry; 95 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

(1) Ophthalmic Data Cohort: Patients and health check-up participants who underwent CFP , OCT or OCTA examinations at Beijing Friendship Hospital, Capital Medical University, from January 2009 to September 2025.(2) Cerebral Data Cohort: Patients and health check-up participants who underwent cerebral MR (Magnetic Resonance) examinations at the same hospital during the corresponding period.(3) Oculo-Cerebral Matched Cohort: Individuals from Beijing Friendship Hospital, Capital Medical University and the UK Biobank (UKB) database who had any of the above ophthalmic imaging examinations, plus cerebral MR scans, and could be matched with complete clinical information.(4) Clinical Correlation Cohort: Individuals from the above cohorts who had complete ICD (International Classification of Diseases) diagnoses, laboratory test results (including blood glucose, blood lipids, uric acid, etc.) and medical order records at Beijing Friendship Hospital, Capital Medical University.

Inclusion criteria

  • Eye data: Images must meet quality standards (no significant artifacts, key structures clearly visible), with complete examination records (including examination date and device model).
  • Brain data: MR images must be free of motion artifacts, with complete sequences (at least including T1-weighted imaging and MRA), and reports must confirm no technical issues.
  • Eye-brain paired cohort: Must contain at least one type of eye image (including CFP, OCT, or OCTA) along with brain MR data, and be linkable to a unique identifier and clinical information in the database
  • Clinical data: Clinical information (such as core biochemical indicators, demographic information, and necessary questionnaire items) must have a missing rate ≤30%, with standardized and clear ICD diagnostic codes, complete laboratory test data, and medical order information (including medication or follow-up recommendations)
  • Prior to initial inclusion in the study, participants must have no history of severe organic diseases (including non-curable or end-stage malignancies, severe heart failure (NYHA Class III-IV), end-stage renal disease (CKD Stage 5), decompensated cirrhosis, or significant functional impairment due to severe cerebrovascular disease sequelae, etc.).

Exclusion criteria

Exclusion Criteria:

  • Ocular examinations in which key features cannot be identified due to conditions such as cataracts or vitreous hemorrhage brain MR images deemed unacceptable in quality due to factors such as metal implants
  • Clinical information (including core biochemical indicators, demographic details, essential questionnaire items, etc.) with a missing rate exceeding 30%
  • Individuals who are pregnant or lactating, those with ocular trauma, congenital ocular malformations, or severe organic diseases.
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
208,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Ophthalmic Data Cohort

    Other: No interventions were involved in this study.

  • Cerebral Data Cohort

    Other: No interventions were involved in this study.

  • Oculo-Cerebral Matched Cohort

    Other: No interventions were involved in this study.

  • Clinical Correlation Cohort

    Other: No interventions were involved in this study.

Interventions

  • OtherNo interventions were involved in this study.

    No interventions were involved in this study.

06

What researchers measure

Primary outcomes

  1. Performance of Systemic Disease Prediction Models

    Age- and sex-stratified Area Under the Receiver Operating Characteristic Curve (AUC)

    Time frame: From the time of model construction and consistency alignment during the study period to the end of the 12-month follow-up after study initiation.

  2. Model generalisation capability.

    Evaluated by Cohen's kappa coefficient across external independent cohorts.

    Time frame: From the completion of model construction and consistency calibration during the study period to the end of the 12-month follow-up after study initiation.

  3. Eye-Brain Mapping Model Performance.

    Measured by correlation coefficient between retinal imaging features and brain neuroimaging metrics.

    Time frame: From the completion of model construction and consistency calibration during the study period to the end of the 12-month follow-up after study initiation.

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07541651
Lead sponsor
Beijing Friendship Hospital
Responsible party
Sponsor
First posted
Apr 21, 2026
Start date
Apr 25, 2026 (estimated)
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Apr 21, 2026

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion